{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:23:16Z","timestamp":1789024996174,"version":"build-2803163510"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["RYC2020-028754-I"],"award-info":[{"award-number":["RYC2020-028754-I"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008369","name":"Sihtasutus Archimedes","doi-asserted-by":"publisher","award":["LMVBS17506"],"award-info":[{"award-number":["LMVBS17506"]}],"id":[{"id":"10.13039\/100008369","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008369","name":"Sihtasutus Archimedes","doi-asserted-by":"publisher","award":["LMVBS17506"],"award-info":[{"award-number":["LMVBS17506"]}],"id":[{"id":"10.13039\/100008369","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008369","name":"Sihtasutus Archimedes","doi-asserted-by":"publisher","award":["LMVBS17506"],"award-info":[{"award-number":["LMVBS17506"]}],"id":[{"id":"10.13039\/100008369","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["MOBJD11"],"award-info":[{"award-number":["MOBJD11"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["2014-2020.4.01.15-0012"],"award-info":[{"award-number":["2014-2020.4.01.15-0012"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002301","name":"Eesti Teadusagentuur","doi-asserted-by":"publisher","award":["PRG230"],"award-info":[{"award-number":["PRG230"]}],"id":[{"id":"10.13039\/501100002301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018225","name":"EuroNanoMed III","doi-asserted-by":"publisher","award":["ECM-CART"],"award-info":[{"award-number":["ECM-CART"]}],"id":[{"id":"10.13039\/100018225","id-type":"DOI","asserted-by":"publisher"}]},{"name":"TRANSCAN3","award":["ReachGLIO"],"award-info":[{"award-number":["ReachGLIO"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-64610-7","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T18:18:15Z","timestamp":1722363495000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Targeting vascular disrupting agent-treated tumor microenvironment with tissue-penetrating nanotherapy"],"prefix":"10.1038","volume":"14","author":[{"given":"Valeria","family":"Sidorenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Scodeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ain","family":"Uustare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Ogibalov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrus","family":"Tasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Tshubrik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liis","family":"Salum\u00e4e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki N.","family":"Sugahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Sim\u00f3n-Gracia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tambet","family":"Teesalu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,30]]},"reference":[{"key":"64610_CR1","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1158\/1078-0432.416.11.2","volume":"11","author":"DW Siemann","year":"2005","unstructured":"Siemann, D. W. et al. Differentiation and definition of vascular-targeted therapies. Clin. Cancer Res. 11, 416\u2013420 (2005).","journal-title":"Clin. Cancer Res."},{"key":"64610_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2010.05.001","author":"DW Siemann","year":"2011","unstructured":"Siemann, D. W. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents. Cancer Treat. Rev. https:\/\/doi.org\/10.1016\/j.ctrv.2010.05.001 (2011).","journal-title":"Cancer Treat. Rev."},{"key":"64610_CR3","first-page":"1829","volume":"57","author":"GG Dark","year":"1997","unstructured":"Dark, G. G. et al. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 57, 1829\u20131834 (1997).","journal-title":"Cancer Res."},{"key":"64610_CR4","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1172\/JCI24586","volume":"115","author":"L Vincent","year":"2005","unstructured":"Vincent, L. et al. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J. Clin. Investig. 115, 2992\u20133006. https:\/\/doi.org\/10.1172\/JCI24586 (2005).","journal-title":"J. Clin. Investig."},{"key":"64610_CR5","first-page":"3408","volume":"62","author":"A Dowlati","year":"2002","unstructured":"Dowlati, A. et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 62, 3408\u20133416 (2002).","journal-title":"Cancer Res."},{"key":"64610_CR6","doi-asserted-by":"publisher","first-page":"4428","DOI":"10.1200\/JCO.2003.12.986","volume":"21","author":"JP Stevenson","year":"2003","unstructured":"Stevenson, J. P. et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: Magnetic resonance imaging evidence for altered tumor blood flow. J. Clin. Oncol. 21, 4428\u20134438. https:\/\/doi.org\/10.1200\/JCO.2003.12.986 (2003).","journal-title":"J. Clin. Oncol."},{"key":"64610_CR7","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1200\/JCO.2003.05.185","volume":"21","author":"GJS Rustin","year":"2003","unstructured":"Rustin, G. J. S. et al. Phase I clinical trial of weekly combretastatin A4 phosphate: Clinical and pharmacokinetic results. J. Clin. Oncol. 21, 2815\u20132822. https:\/\/doi.org\/10.1200\/JCO.2003.05.185 (2003).","journal-title":"J. Clin. Oncol."},{"key":"64610_CR8","doi-asserted-by":"publisher","first-page":"5580","DOI":"10.1200\/jco.2006.24.18_suppl.5580","volume":"24","author":"MM Cooney","year":"2006","unstructured":"Cooney, M. M. et al. Phase II study of combretastatin A4 phosphate (CA4P) in patients with advanced anaplastic thyroid carcinoma (ATC). JCO 24, 5580\u20135580. https:\/\/doi.org\/10.1200\/jco.2006.24.18_suppl.5580 (2006).","journal-title":"JCO"},{"key":"64610_CR9","unstructured":"Study Record | Beta ClinicalTrials.gov n.d. https:\/\/www.clinicaltrials.gov\/study\/NCT00113438?term=Combretastatin%20A4%20Phosphate&rank=4 (accessed July 13, 2023)."},{"key":"64610_CR10","first-page":"2027","volume":"28","author":"DW Siemann","year":"2008","unstructured":"Siemann, D. W. & Shi, W. Dual targeting of tumor vasculature: Combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res. 28, 2027\u20132031 (2008).","journal-title":"Anticancer Res."},{"key":"64610_CR11","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.3390\/ijms21134778","volume":"21","author":"MR Horsman","year":"2020","unstructured":"Horsman, M. R., Wittenborn, T. R., Nielsen, P. S. & Elming, P. B. Tumors resistant to checkpoint inhibitors can become sensitive after treatment with vascular disrupting agents. Int. J. Mol. Sci. 21, 4778. https:\/\/doi.org\/10.3390\/ijms21134778 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"64610_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ymthe.2019.10.010","volume":"28","author":"C Deng","year":"2020","unstructured":"Deng, C. et al. The vascular disrupting agent CA4P improves the antitumor efficacy of CAR-T cells in preclinical models of solid human tumors. Mol. Ther. 28, 75\u201388. https:\/\/doi.org\/10.1016\/j.ymthe.2019.10.010 (2020).","journal-title":"Mol. Ther."},{"key":"64610_CR13","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1259\/bjr\/36205483","volume":"81","author":"GM Tozer","year":"2008","unstructured":"Tozer, G. M. et al. Tumour vascular disrupting agents: Combating treatment resistance. Br. J. Radiol. 81, S12-20. https:\/\/doi.org\/10.1259\/bjr\/36205483 (2008).","journal-title":"Br. J. Radiol."},{"key":"64610_CR14","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/cam4.109","volume":"2","author":"T Fifis","year":"2013","unstructured":"Fifis, T. et al. Treatment with the vascular disruptive agent OXi4503 induces an immediate and widespread epithelial to mesenchymal transition in the surviving tumor. Cancer Med. 2, 595\u2013610. https:\/\/doi.org\/10.1002\/cam4.109 (2013).","journal-title":"Cancer Med."},{"key":"64610_CR15","doi-asserted-by":"publisher","first-page":"15444","DOI":"10.18632\/oncotarget.6999","volume":"7","author":"W Liang","year":"2016","unstructured":"Liang, W., Ni, Y., Chen, F. & Chen, F. H. Tumor resistance to vascular disrupting agents: Mechanisms, imaging, and solutions. Oncotarget 7, 15444\u201315459. https:\/\/doi.org\/10.18632\/oncotarget.6999 (2016).","journal-title":"Oncotarget"},{"key":"64610_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.12.051","author":"BA Salmon","year":"2007","unstructured":"Salmon, B. A. & Siemann, D. W. Characterizing the tumor response to treatment with combretastatin A4 phosphate. Int. J. Radiat. Oncol. Biol. Phys. https:\/\/doi.org\/10.1016\/j.ijrobp.2006.12.051 (2007).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"64610_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1628","author":"GM Tozer","year":"2005","unstructured":"Tozer, G. M., Kanthou, C. & Baguley, B. C. Disrupting tumour blood vessels. Nat. Rev. Cancer https:\/\/doi.org\/10.1038\/nrc1628 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"64610_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/J.JCONREL.2017.10.006","volume":"268","author":"S Sharma","year":"2017","unstructured":"Sharma, S. et al. Vascular changes in tumors resistant to a vascular disrupting nanoparticle treatment. J. Control. Release 268, 49\u201356. https:\/\/doi.org\/10.1016\/J.JCONREL.2017.10.006 (2017).","journal-title":"J. Control. Release"},{"key":"64610_CR19","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1146\/annurev.cellbio.12.1.697","volume":"12","author":"E Ruoslahti","year":"1996","unstructured":"Ruoslahti, E. RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol. 12, 697\u2013715. https:\/\/doi.org\/10.1146\/annurev.cellbio.12.1.697 (1996).","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"64610_CR20","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.drup.2005.10.002","volume":"8","author":"K Temming","year":"2005","unstructured":"Temming, K., Schiffelers, R. M., Molema, G. & Kok, R. J. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist. Updat. 8, 381\u2013402. https:\/\/doi.org\/10.1016\/j.drup.2005.10.002 (2005).","journal-title":"Drug Resist. Updat."},{"key":"64610_CR21","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.3390\/cancers13071711","volume":"13","author":"BS Ludwig","year":"2021","unstructured":"Ludwig, B. S., Kessler, H., Kossatz, S. & Reuning, U. RGD-binding integrins revisited: How recently discovered functions and novel synthetic ligands (re-)shape an ever-evolving field. Cancers (Basel) 13, 1711. https:\/\/doi.org\/10.3390\/cancers13071711 (2021).","journal-title":"Cancers (Basel)"},{"key":"64610_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.apcsb.2014.11.001","volume-title":"Advances in Protein Chemistry and Structural Biology","author":"I Vhora","year":"2015","unstructured":"Vhora, I., Patil, S., Bhatt, P. & Misra, A. Chapter One. Protein- and peptide-drug conjugates: An emerging drug delivery technology. In Advances in Protein Chemistry and Structural Biology Vol. 98 (ed. Donev, R.) 1\u201355 (Academic Press, 2015). https:\/\/doi.org\/10.1016\/bs.apcsb.2014.11.001."},{"key":"64610_CR23","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.ccr.2009.10.013","volume":"8","author":"KN Sugahara","year":"2009","unstructured":"Sugahara, K. N. et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 8, 510\u2013520. https:\/\/doi.org\/10.1016\/j.ccr.2009.10.013 (2009).","journal-title":"Cancer Cell"},{"key":"64610_CR24","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1126\/science.1183057","volume":"328","author":"KN Sugahara","year":"2010","unstructured":"Sugahara, K. N. et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328, 1031\u20131035. https:\/\/doi.org\/10.1126\/science.1183057 (2010).","journal-title":"Science"},{"key":"64610_CR25","doi-asserted-by":"publisher","first-page":"16157","DOI":"10.1073\/pnas.0908201106","volume":"106","author":"T Teesalu","year":"2009","unstructured":"Teesalu, T., Sugahara, K. N., Kotamraju, V. R. & Ruoslahti, E. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. PNAS 106, 16157\u201316162. https:\/\/doi.org\/10.1073\/pnas.0908201106 (2009).","journal-title":"PNAS"},{"key":"64610_CR26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2112457118","volume":"118","author":"G Balistreri","year":"2021","unstructured":"Balistreri, G., Yamauchi, Y. & Teesalu, T. A widespread viral entry mechanism: The C-end Rule motif\u2013neuropilin receptor interaction. Proc. Natl. Acad. Sci. USA 118, e2112457118. https:\/\/doi.org\/10.1073\/pnas.2112457118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"64610_CR27","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1161\/01.RES.0000171756.13554.49","volume":"96","author":"PM Becker","year":"2005","unstructured":"Becker, P. M. et al. Neuropilin-1 regulates vascular endothelial growth factor-mediated endothelial permeability. Circ. Res. 96, 1257\u20131265. https:\/\/doi.org\/10.1161\/01.RES.0000171756.13554.49 (2005).","journal-title":"Circ. Res."},{"key":"64610_CR28","doi-asserted-by":"publisher","first-page":"ra42","DOI":"10.1126\/scisignal.aad3812","volume":"9","author":"L Roth","year":"2016","unstructured":"Roth, L. et al. Neuropilin-1 mediates vascular permeability independently of vascular endothelial growth factor receptor-2 activation. Sci. Signal 9, ra42. https:\/\/doi.org\/10.1126\/scisignal.aad3812 (2016).","journal-title":"Sci. Signal"},{"key":"64610_CR29","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S2468-1253(22)00167-4","volume":"7","author":"A Dean","year":"2022","unstructured":"Dean, A. et al. Dual \u03b1V-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: A first-in-human, open-label, multicentre, phase 1 study. Lancet Gastroenterol. Hepatol. 7, 943\u2013951. https:\/\/doi.org\/10.1016\/S2468-1253(22)00167-4 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"64610_CR30","first-page":"001","volume":"9","author":"KK Buck","year":"2023","unstructured":"Buck, K. K., Dean, A. & McSweeney, T. LSTA1 potentiates complete response in metastatic gastroesophageal adenocarcinoma. Oncol. Cancer Case Rep. 9, 001\u2013003 (2023).","journal-title":"Oncol. Cancer Case Rep."},{"key":"64610_CR31","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.biomaterials.2016.07.023","volume":"104","author":"L Sim\u00f3n-Gracia","year":"2016","unstructured":"Sim\u00f3n-Gracia, L. et al. iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes. Biomaterials 104, 247\u2013257. https:\/\/doi.org\/10.1016\/j.biomaterials.2016.07.023 (2016).","journal-title":"Biomaterials"},{"key":"64610_CR32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jconrel.2015.06.009","volume":"212","author":"KN Sugahara","year":"2015","unstructured":"Sugahara, K. N. et al. A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis. J. Control. Release 212, 59\u201369. https:\/\/doi.org\/10.1016\/j.jconrel.2015.06.009 (2015).","journal-title":"J. Control. Release"},{"key":"64610_CR33","doi-asserted-by":"publisher","first-page":"6979","DOI":"10.3748\/wjg.v19.i41.6979","volume":"19","author":"F Coccolini","year":"2013","unstructured":"Coccolini, F. et al. Peritoneal carcinomatosis. World J. Gastroenterol. 19, 6979\u20136994. https:\/\/doi.org\/10.3748\/wjg.v19.i41.6979 (2013).","journal-title":"World J. Gastroenterol."},{"key":"64610_CR34","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/17512433.2022.2044790","volume":"15","author":"K Harada","year":"2022","unstructured":"Harada, K., Yamashita, K., Iwatsuki, M., Baba, H. & Ajani, J. A. Intraperitoneal therapy for gastric cancer peritoneal carcinomatosis. Expert Rev. Clin. Pharmacol. 15, 43\u201349. https:\/\/doi.org\/10.1080\/17512433.2022.2044790 (2022).","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"64610_CR35","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/sj.bjc.6601490","volume":"90","author":"MF McCarty","year":"2004","unstructured":"McCarty, M. F. et al. ZD6126 inhibits orthotopic growth and peritoneal carcinomatosis in a mouse model of human gastric cancer. Br. J. Cancer 90, 705\u2013711. https:\/\/doi.org\/10.1038\/sj.bjc.6601490 (2004).","journal-title":"Br. J. Cancer"},{"key":"64610_CR36","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1080\/02656736.2017.1312563","volume":"33","author":"C Carlier","year":"2017","unstructured":"Carlier, C. et al. Tumour tissue transport after intraperitoneal anticancer drug delivery. Int. J. Hyperthermia 33, 534\u2013542. https:\/\/doi.org\/10.1080\/02656736.2017.1312563 (2017).","journal-title":"Int. J. Hyperthermia"},{"key":"64610_CR37","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1593\/neo.03205","volume":"6","author":"AW El-Kareh","year":"2004","unstructured":"El-Kareh, A. W. & Secomb, T. W. A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance. Neoplasia 6, 117\u2013127. https:\/\/doi.org\/10.1593\/neo.03205 (2004).","journal-title":"Neoplasia"},{"key":"64610_CR38","doi-asserted-by":"publisher","first-page":"4904","DOI":"10.1038\/ncomms5904","volume":"5","author":"HB Pang","year":"2014","unstructured":"Pang, H. B. et al. An endocytosis pathway initiated through neuropilin-1 and regulated by nutrient availability. Nat. Commun. 5, 4904\u20134916. https:\/\/doi.org\/10.1038\/ncomms5904 (2014).","journal-title":"Nat. Commun."},{"key":"64610_CR39","doi-asserted-by":"publisher","first-page":"18682","DOI":"10.18632\/oncotarget.24588","volume":"9","author":"L Sim\u00f3n-Gracia","year":"2018","unstructured":"Sim\u00f3n-Gracia, L. et al. Application of polymersomes engineered to target p32 protein for detection of small breast tumors in mice. Oncotarget 9, 18682\u201318697. https:\/\/doi.org\/10.18632\/oncotarget.24588 (2018).","journal-title":"Oncotarget"},{"key":"64610_CR40","doi-asserted-by":"publisher","first-page":"17018","DOI":"10.1002\/anie.202016421","volume":"60","author":"L Sim\u00f3n-Gracia","year":"2021","unstructured":"Sim\u00f3n-Gracia, L. et al. Novel anthracycline utorubicin for cancer therapy. Angewandte Chemie 60, 17018\u201317027. https:\/\/doi.org\/10.1002\/anie.202016421 (2021).","journal-title":"Angewandte Chemie"},{"key":"64610_CR41","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2739\/kurumemedj.58.73","volume":"58","author":"A Koga","year":"2011","unstructured":"Koga, A., Aoyagi, K., Imaizumi, T., Miyagi, M. & Shirouzu, K. Comparison between the gastric cancer cell line MKN-45 and the high-potential peritoneal dissemination gastric cancer cell line MKN-45P. Kurume Med. J. 58, 73\u201379. https:\/\/doi.org\/10.2739\/kurumemedj.58.73 (2011).","journal-title":"Kurume Med. J."},{"key":"64610_CR42","unstructured":"Google Colaboratory n.d. https:\/\/colab.research.google.com\/drive\/1aPW2TJPq8ErAWGuf62QUNZB1ZqCw7e8D?usp=sharing (accessed April 22, 2024)."},{"key":"64610_CR43","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10147-006-0616-z","volume":"12","author":"M Miyagi","year":"2007","unstructured":"Miyagi, M., Aoyagi, K., Kato, S. & Shirouzu, K. The TIMP-1 gene transferred through adenovirus mediation shows a suppressive effect on peritoneal metastases from gastric cancer. Int. J. Clin. Oncol. 12, 17\u201324. https:\/\/doi.org\/10.1007\/s10147-006-0616-z (2007).","journal-title":"Int. J. Clin. Oncol."},{"key":"64610_CR44","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/S0360-3016(02)03924-X","volume":"54","author":"DJ Chaplin","year":"2002","unstructured":"Chaplin, D. J. & Hill, S. A. The development of combretastatin A4 phosphate as a vascular targeting agent. Int. J. Radiat. Oncol. Biol. Phys. 54, 1491\u20131496. https:\/\/doi.org\/10.1016\/S0360-3016(02)03924-X (2002).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"64610_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20299","author":"DW Siemann","year":"2004","unstructured":"Siemann, D. W., Chaplin, D. J. & Horsman, M. R. Vascular-targeting therapies for treatment of malignant disease. Cancer https:\/\/doi.org\/10.1002\/cncr.20299 (2004).","journal-title":"Cancer"},{"key":"64610_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6692174","author":"K Grosios","year":"1999","unstructured":"Grosios, K., Holwell, S. E., McGown, A. T., Pettit, G. R. & Bibby, M. C. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br. J. Cancer https:\/\/doi.org\/10.1038\/sj.bjc.6692174 (1999).","journal-title":"Br. J. Cancer"},{"key":"64610_CR47","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nm720","volume":"8","author":"P Laakkonen","year":"2002","unstructured":"Laakkonen, P., Porkka, K., Hoffman, J. A. & Ruoslahti, E. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat. Med. 8, 751\u2013755. https:\/\/doi.org\/10.1038\/nm720 (2002).","journal-title":"Nat. Med."},{"key":"64610_CR48","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/cbic.201500564","volume":"17","author":"L Paasonen","year":"2016","unstructured":"Paasonen, L. et al. New p32\/gC1qR ligands for targeted tumor drug delivery. Chembiochem 17, 570\u2013575. https:\/\/doi.org\/10.1002\/cbic.201500564 (2016).","journal-title":"Chembiochem"},{"key":"64610_CR49","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.nantod.2014.09.001","volume":"9","author":"KY Lin","year":"2014","unstructured":"Lin, K. Y., Kwon, E. J., Lo, J. H. & Bhatia, S. N. Drug-induced amplification of nanoparticle targeting to tumors. Nano Today 9, 550\u2013559. https:\/\/doi.org\/10.1016\/j.nantod.2014.09.001 (2014).","journal-title":"Nano Today"},{"key":"64610_CR50","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1021\/acs.chemrev.5b00241","volume":"116","author":"J Gaitzsch","year":"2016","unstructured":"Gaitzsch, J., Huang, X. & Voit, B. Engineering functional polymer capsules toward smart nanoreactors. Chem. Rev. 116, 1053\u20131093. https:\/\/doi.org\/10.1021\/acs.chemrev.5b00241 (2016).","journal-title":"Chem. Rev."},{"key":"64610_CR51","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jconrel.2017.05.028","volume":"260","author":"P Grossen","year":"2017","unstructured":"Grossen, P., Witzigmann, D., Sieber, S. & Huwyler, J. PEG-PCL-based nanomedicines: A biodegradable drug delivery system and its application. J. Control. Release 260, 46\u201360. https:\/\/doi.org\/10.1016\/j.jconrel.2017.05.028 (2017).","journal-title":"J. Control. Release"},{"key":"64610_CR52","first-page":"6811","volume":"61","author":"DA Beauregard","year":"2001","unstructured":"Beauregard, D. A., Hill, S. A., Chaplin, D. J. & Brindle, K. M. The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability1. Cancer Res. 61, 6811\u20136815 (2001).","journal-title":"Cancer Res."},{"key":"64610_CR53","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1053\/ctrv.2001.0232","volume":"27","author":"AJ Witkamp","year":"2001","unstructured":"Witkamp, A. J., de Bree, E., Van Goethem, R. & Zoetmulder, F. A. N. Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat. Rev. 27, 365\u2013374. https:\/\/doi.org\/10.1053\/ctrv.2001.0232 (2001).","journal-title":"Cancer Treat. Rev."},{"key":"64610_CR54","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/scientificamerican0794-58","volume":"271","author":"RK Jain","year":"1994","unstructured":"Jain, R. K. Barriers to drug delivery in solid tumors. Sci. Am. 271, 58\u201365 (1994).","journal-title":"Sci. Am."},{"key":"64610_CR55","first-page":"189","volume":"19","author":"DJ Chaplin","year":"1999","unstructured":"Chaplin, D. J., Pettit, G. R. & Hill, S. A. Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate. Anticancer Res. 19, 189\u2013195 (1999).","journal-title":"Anticancer Res."},{"key":"64610_CR56","doi-asserted-by":"publisher","first-page":"11520","DOI":"10.1158\/0008-5472.CAN-06-2848","volume":"66","author":"MR Horsman","year":"2006","unstructured":"Horsman, M. R. & Siemann, D. W. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res. 66, 11520\u201311539. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-2848 (2006).","journal-title":"Cancer Res."},{"key":"64610_CR57","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/clpt.2012.108","volume":"92","author":"JR Senior","year":"2012","unstructured":"Senior, J. R. Alanine aminotransferase: A clinical and regulatory tool for detecting liver injury-past, present, and future. Clin. Pharmacol. Ther. 92, 332\u2013339. https:\/\/doi.org\/10.1038\/clpt.2012.108 (2012).","journal-title":"Clin. Pharmacol. Ther."},{"key":"64610_CR58","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S1470-2045(17)30535-1","volume":"18","author":"BE Levis","year":"2017","unstructured":"Levis, B. E., Binkley, P. F. & Shapiro, C. L. Cardiotoxic effects of anthracycline-based therapy: What is the evidence and what are the potential harms?. Lancet Oncol. 18, 445\u2013456. https:\/\/doi.org\/10.1016\/S1470-2045(17)30535-1 (2017).","journal-title":"Lancet Oncol."},{"key":"64610_CR59","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","volume":"31","author":"JV McGowan","year":"2017","unstructured":"McGowan, J. V. et al. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc. Drugs Ther. 31, 63\u201375. https:\/\/doi.org\/10.1007\/s10557-016-6711-0 (2017).","journal-title":"Cardiovasc. Drugs Ther."},{"key":"64610_CR60","doi-asserted-by":"publisher","first-page":"11008","DOI":"10.1021\/acsnano.9b02395","volume":"13","author":"A Zinger","year":"2019","unstructured":"Zinger, A. et al. Collagenase nanoparticles enhance the penetration of drugs into pancreatic tumors. ACS Nano 13, 11008\u201311021. https:\/\/doi.org\/10.1021\/acsnano.9b02395 (2019).","journal-title":"ACS Nano"},{"key":"64610_CR61","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jconrel.2006.05.027","volume":"114","author":"LH Bookbinder","year":"2006","unstructured":"Bookbinder, L. H. et al. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J. Control. Release 114, 230\u2013241. https:\/\/doi.org\/10.1016\/j.jconrel.2006.05.027 (2006).","journal-title":"J. Control. Release"},{"key":"64610_CR62","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/1471-2407-6-280","volume":"6","author":"GU Dachs","year":"2006","unstructured":"Dachs, G. U. et al. Anti-vascular agent combretastatin A-4-P modulates hypoxia inducible factor-1 and gene expression. BMC Cancer 6, 280. https:\/\/doi.org\/10.1186\/1471-2407-6-280 (2006).","journal-title":"BMC Cancer"},{"key":"64610_CR63","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-pathol-012513-104720","volume":"9","author":"GL Semenza","year":"2014","unstructured":"Semenza, G. L. Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu. Rev. Pathol. 9, 47\u201371. https:\/\/doi.org\/10.1146\/annurev-pathol-012513-104720 (2014).","journal-title":"Annu. Rev. Pathol."},{"key":"64610_CR64","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/jnci\/93.4.309","volume":"93","author":"R Bos","year":"2001","unstructured":"Bos, R. et al. Levels of hypoxia-inducible factor-1\u03b1 during breast carcinogenesis. JNCI J. Natl. Cancer Inst. 93, 309\u2013314. https:\/\/doi.org\/10.1093\/jnci\/93.4.309 (2001).","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"64610_CR65","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.3892\/ijo.2013.2068","volume":"43","author":"S Miyake","year":"2013","unstructured":"Miyake, S. et al. HIF-1\u03b1 is a crucial factor in the development of peritoneal dissemination via natural metastatic routes in scirrhous gastric cancer. Int. J. Oncol. 43, 1431\u20131440. https:\/\/doi.org\/10.3892\/ijo.2013.2068 (2013).","journal-title":"Int. J. Oncol."},{"key":"64610_CR66","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.3390\/cancers14112711","volume":"14","author":"C Ucaryilmaz Metin","year":"2022","unstructured":"Ucaryilmaz Metin, C. & Ozcan, G. The HIF-1\u03b1 as a potent inducer of the hallmarks in gastric cancer. Cancers (Basel) 14, 2711. https:\/\/doi.org\/10.3390\/cancers14112711 (2022).","journal-title":"Cancers (Basel)"},{"key":"64610_CR67","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1091\/mbc.e04-12-1082","volume":"16","author":"KD Cowden Dahl","year":"2005","unstructured":"Cowden Dahl, K. D., Robertson, S. E., Weaver, V. M. & Simon, M. C. Hypoxia-inducible factor regulates \u03b1v\u03b23 integrin cell surface expression. MBoC 16, 1901\u20131912. https:\/\/doi.org\/10.1091\/mbc.e04-12-1082 (2005).","journal-title":"MBoC"},{"key":"64610_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-021-03682-z","volume":"12","author":"R Fu","year":"2021","unstructured":"Fu, R. et al. HIF-1\u03b1 promoted vasculogenic mimicry formation in lung adenocarcinoma through NRP1 upregulation in the hypoxic tumor microenvironment. Cell Death Dis. 12, 1\u201311. https:\/\/doi.org\/10.1038\/s41419-021-03682-z (2021).","journal-title":"Cell Death Dis."},{"key":"64610_CR69","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1126\/science.aaf4405","volume":"352","author":"EB Rankin","year":"2016","unstructured":"Rankin, E. B. & Giaccia, A. J. Hypoxic control of metastasis. Science 352, 175\u2013180. https:\/\/doi.org\/10.1126\/science.aaf4405 (2016).","journal-title":"Science"},{"key":"64610_CR70","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.3390\/cells8121602","volume":"8","author":"X Li","year":"2019","unstructured":"Li, X. et al. The tumor vessel targeting strategy: A double-edged sword in tumor metastasis. Cells 8, 1602. https:\/\/doi.org\/10.3390\/cells8121602 (2019).","journal-title":"Cells"},{"key":"64610_CR71","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1111\/cas.14942","volume":"112","author":"T Tomita","year":"2021","unstructured":"Tomita, T., Kato, M. & Hiratsuka, S. Regulation of vascular permeability in cancer metastasis. Cancer Sci. 112, 2966\u20132974. https:\/\/doi.org\/10.1111\/cas.14942 (2021).","journal-title":"Cancer Sci."},{"key":"64610_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173692","volume":"891","author":"R Smolarczyk","year":"2021","unstructured":"Smolarczyk, R., Czapla, J., Jarosz-Biej, M., Czerwinski, K. & Cicho\u0144, T. Vascular disrupting agents in cancer therapy. Eur. J. Pharmacol. 891, 173692. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173692 (2021).","journal-title":"Eur. J. Pharmacol."},{"key":"64610_CR73","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.3390\/jcm11051456","volume":"11","author":"F Gronau","year":"2022","unstructured":"Gronau, F. et al. HIPEC in peritoneal metastasis of gastric origin: A systematic review of regimens and techniques. JCM 11, 1456. https:\/\/doi.org\/10.3390\/jcm11051456 (2022).","journal-title":"JCM"},{"key":"64610_CR74","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.addr.2016.07.001","volume":"108","author":"GR Dakwar","year":"2017","unstructured":"Dakwar, G. R. et al. Nanomedicine-based intraperitoneal therapy for the treatment of peritoneal carcinomatosis\u2014Mission possible?. Adv. Drug Deliv. Rev. 108, 13\u201324. https:\/\/doi.org\/10.1016\/j.addr.2016.07.001 (2017).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"64610_CR75","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1158\/1535-7163.MCT-15-0713-T","volume":"15","author":"L Sim\u00f3n-Gracia","year":"2016","unstructured":"Sim\u00f3n-Gracia, L. et al. Paclitaxel-loaded polymersomes for enhanced intraperitoneal chemotherapy. Mol. Cancer Ther. 15, 670\u2013679. https:\/\/doi.org\/10.1158\/1535-7163.MCT-15-0713-T (2016).","journal-title":"Mol. Cancer Ther."},{"key":"64610_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40661-017-0058-5","volume":"5","author":"R Grisham","year":"2018","unstructured":"Grisham, R., Ky, B., Tewari, K. S., Chaplin, D. J. & Walker, J. Clinical trial experience with CA4P anticancer therapy: Focus on efficacy, cardiovascular adverse events, and hypertension management. Gynecol. Oncol. Res. Pract. 5, 1. https:\/\/doi.org\/10.1186\/s40661-017-0058-5 (2018).","journal-title":"Gynecol. Oncol. Res. Pract."},{"key":"64610_CR77","first-page":"673","volume":"20","author":"S Young","year":"2022","unstructured":"Young, S. et al. The role of cytoreductive surgery and intraperitoneal chemotherapy in gastric cancer. Clin. Adv. Hematol. Oncol. 20, 673\u2013682 (2022).","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"64610_CR78","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1451","author":"AH Colby","year":"2017","unstructured":"Colby, A. H. et al. Nanoparticle drug delivery systems for peritoneal cancers: A case study of the design, characterization, and development of the expansile nanoparticle. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. https:\/\/doi.org\/10.1002\/wnan.1451 (2017).","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"64610_CR79","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.3390\/molecules23051190","volume":"23","author":"L Sim\u00f3n-Gracia","year":"2018","unstructured":"Sim\u00f3n-Gracia, L., Hunt, H. & Teesalu, T. Peritoneal carcinomatosis targeting with tumor homing peptides. Molecules 23, 1190. https:\/\/doi.org\/10.3390\/molecules23051190 (2018).","journal-title":"Molecules"},{"key":"64610_CR80","doi-asserted-by":"publisher","first-page":"808","DOI":"10.3390\/molecules25040808","volume":"25","author":"P Scodeller","year":"2020","unstructured":"Scodeller, P. & Asciutto, E. K. Targeting tumors using peptides. Molecules 25, 808. https:\/\/doi.org\/10.3390\/molecules25040808 (2020).","journal-title":"Molecules"},{"key":"64610_CR81","doi-asserted-by":"publisher","first-page":"5232","DOI":"10.1038\/srep05232","volume":"4","author":"S Hussain","year":"2014","unstructured":"Hussain, S., Rodriguez-Fernandez, M., Braun, G. B., Doyle, F. J. & Ruoslahti, E. Quantity and accessibility for specific targeting of receptors in tumours. Sci. Rep. 4, 5232. https:\/\/doi.org\/10.1038\/srep05232 (2014).","journal-title":"Sci. Rep."},{"key":"64610_CR82","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1021\/bc1004284","volume":"22","author":"JS Josan","year":"2011","unstructured":"Josan, J. S. et al. Cell-specific targeting by heterobivalent ligands. Bioconjug. Chem. 22, 1270\u20131278. https:\/\/doi.org\/10.1021\/bc1004284 (2011).","journal-title":"Bioconjug. Chem."},{"key":"64610_CR83","doi-asserted-by":"publisher","first-page":"5966","DOI":"10.1021\/ja400951g","volume":"135","author":"EM Munoz","year":"2013","unstructured":"Munoz, E. M., Correa, J., Riguera, R. & Fernandez-Megia, E. Real-time evaluation of binding mechanisms in multivalent interactions: A surface Plasmon resonance kinetic approach. J. Am. Chem. Soc. 135, 5966\u20135969. https:\/\/doi.org\/10.1021\/ja400951g (2013).","journal-title":"J. Am. Chem. Soc."},{"key":"64610_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2019.119373","volume":"219","author":"P Lingasamy","year":"2019","unstructured":"Lingasamy, P. et al. Bi-specific tenascin-C and fibronectin targeted peptide for solid tumor delivery. Biomaterials 219, 119373. https:\/\/doi.org\/10.1016\/j.biomaterials.2019.119373 (2019).","journal-title":"Biomaterials"},{"key":"64610_CR85","doi-asserted-by":"publisher","first-page":"5809","DOI":"10.1038\/s41598-020-62760-y","volume":"10","author":"P Lingasamy","year":"2020","unstructured":"Lingasamy, P. et al. Tumor-penetrating peptide for systemic targeting of Tenascin-C. Sci. Rep. 10, 5809. https:\/\/doi.org\/10.1038\/s41598-020-62760-y (2020).","journal-title":"Sci. Rep."},{"key":"64610_CR86","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1021\/acs.molpharmaceut.0c00226","volume":"17","author":"A Lepland","year":"2020","unstructured":"Lepland, A. et al. Targeting pro-tumoral macrophages in early primary and metastatic breast tumors with the CD206-binding mUNO peptide. Mol. Pharm. 17, 2518\u20132531. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.0c00226 (2020).","journal-title":"Mol. Pharm."},{"key":"64610_CR87","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1172\/JCI84427","volume":"126","author":"A-T Henze","year":"2016","unstructured":"Henze, A.-T. & Mazzone, M. The impact of hypoxia on tumor-associated macrophages. J. Clin. Investig. 126, 3672\u20133679. https:\/\/doi.org\/10.1172\/JCI84427 (2016).","journal-title":"J. Clin. Investig."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-64610-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-64610-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-64610-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T18:30:27Z","timestamp":1722364227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-64610-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,30]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["64610"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-64610-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,30]]},"assertion":[{"value":"5 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TT and KNS are inventors of patents on CendR peptides and shareholders of Lisata Therapeutics, a company that develops iRGD peptide for cancer therapy. VS, LSG, OT, AT, AU, IO, and TT are inventors of patent application for Utorubicin (application TD 40725\/ST). PS and LS have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17513"}}